Global Irbesartan Market Size By Type (Combination Drugs, Prescribed Drugs), By Application (Hyperlipidemia, High Blood Pressure), By Region, And Segment Forecasts, 2023 to 2032

The Global Irbesartan Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 6.7 billion by 2031, growing at a CAGR of 5.7% during the forecast period (2023–2031). Irbesartan, an angiotensin II receptor antagonist, is primarily used for treating hypertension and diabetic nephropathy. The market is expanding due to the increasing global burden of cardiovascular diseases and diabetes, a growing geriatric population, and rising awareness regarding hypertension management. Generic availability and expanding healthcare infrastructure in emerging markets are also accelerating market growth.

Drivers:

1. Rising Prevalence of Hypertension and Diabetes:

With hypertension and diabetes reaching epidemic levels worldwide, especially in middle-aged and elderly populations, irbesartan is in increasing demand for the effective management of these chronic conditions.

2. Increasing Geriatric Population:

Older adults are more prone to cardiovascular and kidney-related complications, leading to higher prescriptions of irbesartan, particularly in developed nations with aging demographics.

3. Generic Drug Penetration:

The availability of cost-effective generic versions of irbesartan has improved accessibility, particularly in low- and middle-income countries, enhancing market penetration.

Restraints:

1. Side Effects and Product Recalls:

Irbesartan has occasionally been recalled due to the presence of nitrosamine impurities, which has led to regulatory scrutiny and affected consumer trust.

2. Patent Expiry and Market Competition:

The expiration of patents has opened the market to numerous generic players, which has resulted in price erosion and intensified competition, challenging revenue growth for branded drug manufacturers.

Opportunity:

1. Market Expansion in Emerging Economies:

Rising health awareness, increasing healthcare spending, and supportive government initiatives in regions like Asia-Pacific and Latin America offer lucrative opportunities for irbesartan manufacturers.

2. Combination Therapies:

The growing trend of combination drug therapies for hypertension and related disorders is opening new avenues for irbesartan, often used with hydrochlorothiazide and other agents for better efficacy.

Market by System Type Insights:

The Tablet form of irbesartan dominated the market in 2023, accounting for the largest revenue share due to ease of administration, patient compliance, and widespread prescription by healthcare professionals. Other forms like capsules and oral solutions are present but hold relatively minor market shares.

Market by End-use Insights:

The Hospital Pharmacies segment led the market in 2023. Hospitals remain the primary channel for chronic disease management, including hypertension, especially in developing regions where hospital-based prescriptions are more common. Retail Pharmacies and Online Pharmacies are also expanding rapidly due to increasing convenience and the rise in e-pharmacy services.

Market by Regional Insights:

North America held the largest market share in 2023, supported by a high prevalence of hypertension, strong healthcare infrastructure, and high healthcare expenditure. Asia-Pacific is projected to witness the fastest growth during the forecast period, driven by rising chronic disease burden, growing population, and improving access to generics in countries like India and China.

Competitive Scenario:

Key players in the Global Irbesartan Market include Sanofi, Teva Pharmaceuticals, Mylan N.V., Torrent Pharmaceuticals, Lupin Limited, Zydus Lifesciences, Cipla, Accord Healthcare, and Alembic Pharmaceuticals. Companies are actively engaging in product launches, partnerships, and regulatory approvals to gain competitive advantage.

Scope of Work – Global Irbesartan Market

Key Market Developments:

June 2024: Teva Pharmaceuticals received FDA approval for a new generic version of irbesartan with enhanced formulation stability.

March 2023: Lupin Limited launched a combination therapy involving irbesartan and hydrochlorothiazide in select Asia-Pacific markets.

September 2022: Torrent Pharmaceuticals expanded its production facility in India to meet the rising demand for irbesartan and other antihypertensive medications.

FAQs:

1) What is the current market size of the Global Irbesartan Market?

The Global Irbesartan Market was valued at USD 4.3 billion in 2023.

2) What is the major growth driver of the Global Irbesartan Market?

The major driver is the rising prevalence of hypertension and diabetes worldwide.

3) Which is the largest region during the forecast period in the Global Irbesartan Market?

North America accounted for the largest share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in Global Irbesartan Market?

The Tablet segment held the largest share by form, and Hospital Pharmacies by end-use in 2023.

5) Who are the key market players in the Global Irbesartan Market?

Key players include Sanofi, Teva Pharmaceuticals, Torrent Pharmaceuticals, Lupin, and Cipla.